Ventriculoperitoneal shunt for XXXX caused by central nervous system metastasis.

@entity1 @entity1276 @entity5 @entity2722 @entity2507 @entity3
The development of better diagnostic tools and therapeutic modalities has increased the incidence of central nervous system (CNS) @entity3 in @entity5 @entity1 . @entity1276 can result from CNS @entity3 and frustrate @entity5 treatment. The authors sought to investigate the outcomes and the roles of ventriculoperitoneal shunts (VPS) in @entity1 with CNS @entity3 . The medical records of 50 consecutive @entity1 who underwent VPS for @entity1276 related to CNS @entity3 were analyzed retrospectively. Data included features of primary @entity5 , CNS involvement, clinical course and surgical outcome. Median @entity1 age was 55.0  years (range 25-77), and 30 female and 20 male @entity1 were included in the study. At the time of VPS, 10 @entity1 had parenchymal metastases only and 40 @entity1 had @entity2722 ( @entity2722 ). Symptom improvement was observed postoperatively in 40 @entity1 (80%), mean Karnofsky performance status (KPS) scale change was from 37.8 to 46.0, and median survival from VPS was 3.0  months (2  days to 54  months). A ventricular opening pressure of >30  cm @entity2507 (HR 6.44, 95% CI 1.26-32.9, P  =  0.02) and further @entity5 treatment after VPS (HR 0.17, 95% CI 0.07-0.42, P  <  0.0001) were found to be independent risk factors of poorer and better survival, respectively. @entity1276 in CNS @entity3 requiring VPS is commonly associated with @entity2722 . VPS is an effective palliative measure and an adequate @entity5 treatment after VPS may provide the best means of improving survival.
